- Myriad Genetics (MYGN -6%) slides as SunTrust raises pricing questions (something MYGN investors certainly do not want to hear about).
- "The most imminent threat from new competitors for BRACAnalysis is not market share, buy pricing pressures," analyst Amit Hazan says, adding that "private insurer re-evaluation is currently ongoing ... and could realistically drive the price down by as much as 50% over the next two years."
- MYGN initiated at Reduce.
- Price target is $17.
From other sites
at Nasdaq.com (Apr 8, 2015)
at Zacks.com (Mar 9, 2015)
at Zacks.com (Mar 2, 2015)
at Benzinga.com (Feb 25, 2015)
at Nasdaq.com (Feb 12, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs